Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.35 |
| ▸ | ADH1B | P00325 | 1/20 | 0.34 |
| ▸ | ADH1C | P00326 | 1/20 | 0.34 |
| ▸ | ADH1A | P07327 | 1/20 | 0.34 |
| ▸ | ADH4 | P08319 | 1/20 | 0.34 |
| ▸ | ADH7 | P40394 | 1/20 | 0.34 |
| ▸ | FDPS | P14324 | 4/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.33 |
| ▸ | GAPDH | P04406 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28618097 | 0.98 | TSHR (0.48) | TSHRSMN1; SMN2OPRM1LMNADNM1 | |
| SCHEMBL28608681 | 0.98 | TSHR (0.48) | TSHRSMN1; SMN2OPRM1LMNADNM1 | |
| SCHEMBL26089412 | 0.92 | — | — | |
| SCHEMBL8606116 | 0.81 | — | — | |
| SCHEMBL15170448 | 0.80 | TSHR (0.50) | TSHRSMN1; SMN2OPRM1LMNADNM1 | |
| SCHEMBL4274210 | 0.79 | TSHR (0.54) | TSHRSMN1; SMN2OPRM1LMNADNM1 | |
| SCHEMBL9208137 | 0.78 | TSHR (0.48) | TSHRSMN1; SMN2OPRM1LMNADNM1 | |
| SCHEMBL4267303 | 0.78 | TSHR (0.48) | TSHRSMN1; SMN2OPRM1LMNADNM1 | |
| SCHEMBL10600803 | 0.78 | TSHR (0.48) | TSHRSMN1; SMN2OPRM1LMNADNM1 | |
| SCHEMBL27732481 | 0.78 | TSHR (0.48) | TSHRSMN1; SMN2OPRM1LMNADNM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118139926-A | Resin composition | 株式会社可乐丽 | 2024-06-04 | — | — | CN | disclosed |
| CN-118139909-A | Beta-methyl-delta-valerolactone based polymer | 株式会社可乐丽 | 2024-06-04 | — | — | CN | disclosed |
| CN-112771046-B | Other substituted triazoloquinoxaline derivatives | 格吕伦塔尔有限公司 | 2023-09-19 | — | — | CN | disclosed |
| CN-112673009-B | Substituted triazoloquinoxaline derivatives | 格吕伦塔尔有限公司 | 2023-09-19 | — | — | CN | disclosed |
| WO-2023068346-A1 | Β-METHYL-δ-VALEROLACTONE POLYMER | 株式会社クラレ | 2023-04-27 | — | — | WO | disclosed |
| WO-2023068345-A1 | Β-METHYL-δ-VALEROLACTONE POLYMER | 株式会社クラレ | 2023-04-27 | — | — | WO | disclosed |
| WO-2023068348-A1 | RESIN COMPOSITION | 株式会社クラレ | 2023-04-27 | — | — | WO | disclosed |
| US-8101650-B2 | Method for treating a immunology-related disease | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-01-24 | — | — | US | disclosed |
| US-8067396-B2 | Amino alcohol compounds or phosphonic acid derivatives thereof | SANKYO COMPANY, LIMITED (JP) | 2011-11-29 | — | — | US | disclosed |
| US-20100035842-A1 | Amino alcohol compounds or phosphonic acid derivatives thereof | SANKYO COMPANY, LIMITED (JP) | 2010-02-11 | — | — | US | disclosed |
| EP-1471054-A1 | AMINO ALCOHOL DERIVATIVE OR PHOSPHONIC ACID DERIVATIVE AND MEDICINAL COMPOSITION CONTAINING THESE | Sankyo Company, Limited (JP) | 2004-10-27 | — | — | EP | disclosed |
| US-20040132784-A1 | Amino alcohol derivatives | SANKYO COMPANY, LIMITED (JP) | 2004-07-08 | — | — | US | disclosed |
| CN-1494540-A | Amino alcohol derivatives | ������������ʽ���� | 2004-05-05 | — | — | CN | disclosed |
| US-6723745-B2 | PREVENTION OR TREATMENT OF AUTOIMMUNE DISEASE IN WARM BLOODED ANIMAL | SANKYO COMPANY, LIMITED (JP) | 2004-04-20 | — | — | US | disclosed |
| US-20030236297-A1 | Amino alcohol derivatives | SANKYO COMPANY, LIMITED (JP) | 2003-12-25 | — | — | US | disclosed |
| EP-1300405-A1 | AMINO ALCOHOL DERIVATIVES | Sankyo Company, Limited (JP) | 2003-04-09 | — | — | EP | disclosed |
| US-6231934-B1 | Alkenyl compound, liquid crystal composition, and liquid crystal display device | CHISSO CORPORATION (JP) | 2001-05-15 | — | — | US | disclosed |
| US-6124005-A | EXCELLENT COMPATIBILITY WITH OTHER LIQUID CRYSTAL MATERIALS, ESPECIALLY AT LOW TEMPERATURES, HIGH VOLTAGE HOLDING RATIO, LOW THRESHOLD VOLTAGE, SMALL TEMPERATURE DEPENDENCY, BROAD LIQUID PHASE TEMPERATURE RANGE | CHISSO CORPORATION (JP) | 2000-09-26 | — | — | US | disclosed |
| EP-0926120-A1 | FLUORINATED ALKYL ETHER COMPOUNDS, LIQUID-CRYSTAL COMPOSITIONS, AND LIQUID-CRYSTAL DISPLAY DEVICES | CHISSO CORPORATION (JP) | 1999-06-30 | — | — | EP | disclosed |
| EP-0893421-A1 | ALKENYL COMPOUNDS, LIQUID CRYSTAL COMPOSITIONS, AND LIQUID CRYSTAL DISPLAY DEVICES | CHISSO CORPORATION (JP) | 1999-01-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236297-A1 | Amino alcohol derivatives | CD4, ADH1C, ADH1A | TSHR 1187/4885SMN1; SMN2 4220/4885OPRM1 163/4885 |
| US-20040132784-A1 | Amino alcohol derivatives | CD4, ADH1C, ADH1A | TSHR 1187/4885SMN1; SMN2 4220/4885OPRM1 163/4885 |
| US-20100035842-A1 | Amino alcohol compounds or phosphonic acid derivatives thereof | PHOSPHO1, ADH1C, ADH1A | TSHR 744/4885SMN1; SMN2 4797/4885OPRM1 753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.